velphoro
vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - - mediċini għal-kura tal-iperkalimja u ' l-iperphosphatemija - velphoro huwa indikat għall-kontroll ta 'livelli ta' fosfru fis-serum f'pazjenti b'mard tal-kliewi kroniku adulti (ckd) fuq emodijaliżi (hd) jew dijalisi peritoneali (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.
elonva
n.v. organon - corifollitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).
sycrest
n.v. organon - asenapine (as maleate) - disturb bipolari - psikolettiċi - sycrest huwa indikat għall-kura ta 'episodji manijaċi moderati sa severi assoċjati ma' disturb bipolari i fl-adulti.
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosoppressanti - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influwenza, bniedem - vaċċini kontra l-influwenza, influwenza, ħaj attenwat - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. l-użu ta 'fluenz tetra għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.
victrelis
merck sharp dohme ltd - boceprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - victrelis huwa indikat għall-kura ta ' l-infezzjoni tal-ġenotip-1 kronika epatite-c (chc), flimkien mal-peginterferon alfa u ribavirin, fil-pazjenti adulti b ' mard tal-fwied kompensat li huma mhux ittrattat minn qabel jew li jkunu fallew terapija qabel.
puregon
n.v. organon - follitropin beta - infertility; hypogonadism - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - fil-mara:puregon huwa indikat għall-kura ta 'nisa infertilità fis-sitwazzjonijiet kliniċi li ġejjin:meta ma jkunx hemm ovulazzjoni (inkluż l-sindromu tal-ovarji poliċistiċi, pcos) fin-nisa li ġew jirrispondux għall-kura bi clomifene citrate;iperstimulazzjoni kkontrollata ta' l-ovarji sabiex tistimula l-iżvilupp tal-follikuli multipli fi programmi ta ' riproduzzjoni medikament assistiti (e. fil-fertilizzazzjoni in vitro / - trasferiment tal-embriju (ivf/et), il-gameti intrafallopian trasferiment (gift) u intracytoplasmic-injezzjoni ta ' l-isperma (icsi)). fir-raġel:defiċjenza ta ' spermatoġenesi minħabba ipogonadiżmu ipogonadotrofiku.
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psorajiżi - immunosoppressanti - treatment of moderate-to-severe plaque psoriasis in adults.
optimark
mallinckrodt deutschland gmbh - gadoversetamide - immaġni tar-reżonanza manjetika - midja ta 'kuntrast - dan il-prodott mediċinali huwa għal użu dijanjostiku biss. optimark hu indikat għall-użu mal-immaġni tar-reżonanza manjetika (mri) tas-sistema nervuża ċentrali (cns) u l-fwied. jipprovdi titjib tal-kuntrast u jiffaċilita l-viżwalizzazzjoni u jgħin fil-karatterizzazzjoni tal-leżjonijiet fokali u strutturi anormali fis-cns u fil-fwied f'pazjenti b'magħrufa jew issuspettata patoloġija.
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.